Who Owns Gene Editing? Patents in the Time of CRISPR
Biochemist, Vol. 38, p. 26 (2016)
4 Pages Posted: 16 Feb 2017
Date Written: April 5, 2016
Abstract
New gene-editing technologies, like CRISPR, promise revolutionary advances in biology and medicine. However, several patent disputes in the USA and UK may have complicated who can use CRISPR. What does this mean for the future of gene editing?
Keywords: intellectual property, patent, biotech, biotechnology, crispr, genetics
JEL Classification: K00, K23, K41, O3, O34, D23, K11
Suggested Citation: Suggested Citation
Sherkow, Jacob S., Who Owns Gene Editing? Patents in the Time of CRISPR (April 5, 2016). Biochemist, Vol. 38, p. 26 (2016), NYLS Legal Studies Research Paper No. 2915853, Available at SSRN: https://ssrn.com/abstract=2915853
Do you have negative results from your research you’d like to share?
Feedback
Feedback to SSRN
If you need immediate assistance, call 877-SSRNHelp (877 777 6435) in the United States, or +1 212 448 2500 outside of the United States, 8:30AM to 6:00PM U.S. Eastern, Monday - Friday.